Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
- Data from Phase 2 chronic osteoarthritis pain study of Oral CR845 to be presented in poster session at PAINWeek
STAMFORD, Conn., Aug. 31, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at PAINWeek, to be held September 5-9, 2017 in Las Vegas, NV and the American Association of Nurse Anesthetists (AANA) Nurse Anesthesia Annual Congress, to be held September 8-12, 2017 in Seattle, WA.
Presentations will include clinical trial data for CR845, Cara’s first-in-class peripherally selective kappa opioid agonist being developed for the treatment of acute and chronic pain, as well as chronic kidney disease-associated pruritus.
PAINWeek
Details for the presentations are as follows:
CR845 Poster Presentation:
| Poster Title: | "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee" | |
| Poster Number: | 101 | |
| Date/ Time: | Thursday, September 7, 2017; 6:30-8:30 p.m. PT |
Satellite Symposium:
| Presentation Title: | "A Potential New Path of Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)" | |
| Date/ Time: | Friday, September 8, 2017; 12:30 - 1:30 p.m. PT | |
| Moderator: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics | |
| Faculty: | Michael J. Brennan, M.D., Medical Director, the Pain Center of Fairfield; Senior Attending Physician, Department of Medicine, Bridgeport Hospital; Associate Director, Chronic Pain and Recovery Program, Silver Hill Hospital |
For information about PAINWeek, visit http://www.painweek.org/.
AANA Nurse Anesthesia Annual Congress
Details for the satellite symposium are as follows:
| Presentation Title: | "A Potential New Path of Pain Relief" | |
| Date/ Time: | Sunday, September 10, 2017; 4:00 – 5:00 p.m. PT | |
| Speakers: | Jackie Rowles, D.N.P., M.B.A., C.R.N.A., A.N.P.-B.C., D.A.A.P.M., F.A.A.N., Director, DNP Nurse Anesthesia Program, Marian University; Associate Professor, Leighton School of Nursing; Clinical Instructor, College of Osteopathic Medicine; Adjunct Faculty, Nurse Anesthesia Pain Management Fellowship, Texas Christian University | |
| Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
For information about AANA, visit http://aana2017.com/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system. CR845 has demonstrated initial efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. In patients with moderate-to-severe CKD-associated pruritus, CR845 has demonstrated its potential to reduce itch and improve quality of life.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
